Arcturus Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Arcturus Therapeutics Holdings
ARCT Stock  USD 8.67  0.11  1.25%   
Analyzing historical trends in various income statement and balance sheet accounts from Arcturus Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Arcturus Therapeutics' valuation are summarized below:
Gross Profit
-70.9 M
Profit Margin
(0.49)
Market Capitalization
235.4 M
Enterprise Value Revenue
0.6326
Revenue
122.1 M
There are currently one hundred twenty fundamental signals for Arcturus Therapeutics Holdings that can be evaluated and compared over time across rivals. All traders should validate Arcturus Therapeutics' prevailing fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 433 M in 2025. Enterprise Value is likely to gain to about 236 M in 2025

Arcturus Therapeutics Total Revenue

145.31 Million

Check Arcturus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcturus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.7 M, Interest Expense of 0.0 or Selling General Administrative of 55.5 M, as well as many indicators such as Price To Sales Ratio of 3.15, Dividend Yield of 0.001 or PTB Ratio of 2.0. Arcturus financial statements analysis is a perfect complement when working with Arcturus Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Arcturus Stock
Check out the analysis of Arcturus Therapeutics Correlation against competitors.

Arcturus Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets194 M344.1 M166.5 M
Slightly volatile
Other Current Liabilities30.7 M29.3 M10.5 M
Slightly volatile
Total Current Liabilities37.7 M65.5 M32.4 M
Slightly volatile
Property Plant And Equipment Net38 M36.2 M11.9 M
Slightly volatile
Accounts Payable4.3 M7.2 M3.7 M
Slightly volatile
Cash151.7 M237 M130.2 M
Slightly volatile
Non Current Assets Total40 M38.1 M13.9 M
Slightly volatile
Non Currrent Assets Other2.3 M2.2 M637.9 K
Slightly volatile
Cash And Short Term Investments163.8 M237 M140.5 M
Slightly volatile
Net Receivables4.4 M4 M3.8 M
Slightly volatile
Common Stock Total Equity28.4 K29.9 K52.6 K
Very volatile
Common Stock Shares Outstanding28.4 M27 M12.3 M
Slightly volatile
Liabilities And Stockholders Equity194 M344.1 M166.5 M
Slightly volatile
Other Current Assets68.2 M65 M13.6 M
Slightly volatile
Other Stockholder Equity724.2 M689.8 M270.4 M
Slightly volatile
Total Liabilities62.5 M103.1 M53.6 M
Slightly volatile
Property Plant And Equipment Gross50.4 M48 M14 M
Slightly volatile
Total Current Assets179.7 M306 M154.2 M
Slightly volatile
Common Stock46.2 K24.3 K53.5 K
Very volatile
Short and Long Term Debt Total33.5 M28.6 M19.9 M
Slightly volatile
Short Term Debt6.7 M7.1 M7.2 M
Slightly volatile
Net Tangible Assets275.6 M262.4 M123.6 M
Slightly volatile
Property Plant Equipment54.3 M51.7 M13.9 M
Slightly volatile
Capital Surpluse695.1 M662 M293.3 M
Slightly volatile
Other Liabilities14 M26.3 M10.8 M
Slightly volatile
Current Deferred Revenue23.5 M21.9 M15.1 M
Slightly volatile
Non Current Liabilities Total38.9 M37.6 M23.6 M
Slightly volatile
Short and Long Term Debt73.2 M69.8 M18.3 M
Slightly volatile
Net Invested Capital227.1 M241 M132.2 M
Slightly volatile
Net Working Capital225.7 M240.5 M134.1 M
Slightly volatile
Long Term Debt49.1 M46.7 M21 M
Slightly volatile
Long Term Debt Total49.1 M46.7 M21 M
Slightly volatile
Capital Stock41.4 K24.3 K132 K
Slightly volatile
Capital Lease Obligations20.2 M28.6 M11.3 M
Slightly volatile
Deferred Long Term Liabilities17.5 M22.9 M16.5 M
Slightly volatile
Non Current Liabilities Other424.9 K447.3 K3.8 M
Slightly volatile

Arcturus Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.7 M3.5 M994 K
Slightly volatile
Selling General Administrative55.5 M52.8 M21.1 M
Slightly volatile
Other Operating Expenses186.4 M177.5 M76.3 M
Slightly volatile
Research Development204.9 M195.2 M69.2 M
Slightly volatile
Total Operating Expenses182.7 M174 M45.4 M
Slightly volatile
Interest Income16 M15.2 M3.4 M
Slightly volatile
Reconciled Depreciation3.7 M3.5 M1.1 M
Slightly volatile
Selling And Marketing Expenses2.4 M2.7 M2.9 M
Slightly volatile

Arcturus Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation39.9 M38 M12.4 M
Slightly volatile
Begin Period Cash Flow366.3 M348.9 M133.1 M
Slightly volatile
Depreciation3.7 M3.5 M979.4 K
Slightly volatile
End Period Cash Flow161 M293.9 M138.1 M
Slightly volatile
Sale Purchase Of Stock1.5 M1.6 M52.3 M
Very volatile
Change To Netincome43.7 M41.6 M13.8 M
Slightly volatile
Cash Flows Other Operating36.2 M34.4 M15.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.153.310920.743
Very volatile
Dividend Yield0.0010.00110.0028
Slightly volatile
Days Sales Outstanding9.9610.481438.6209
Pretty Stable
Stock Based Compensation To Revenue0.360.27450.4268
Pretty Stable
Capex To Depreciation0.170.18282.6489
Slightly volatile
Payables Turnover0.470.49263.8476
Slightly volatile
Sales General And Administrative To Revenue0.360.38170.9206
Very volatile
Research And Ddevelopement To Revenue2.441.41022.7432
Pretty Stable
Capex To Revenue0.00440.00470.0535
Pretty Stable
Cash Per Share9.828.778811.3783
Pretty Stable
Days Payables Outstanding857741668
Very volatile
Income Quality0.70.73820.8406
Pretty Stable
Current Ratio9.014.67227.9161
Pretty Stable
Receivables Turnover36.5634.823619.8081
Pretty Stable
Capex Per Share0.02280.0240.0725
Slightly volatile
Revenue Per Share2.755.12552.9442
Slightly volatile
Interest Debt Per Share0.761.05740.8803
Slightly volatile
Debt To Assets0.07880.0830.7027
Slightly volatile
Graham Number7.228.128.8486
Slightly volatile
Days Of Payables Outstanding857741668
Very volatile
Ebt Per Ebit1.030.84610.9507
Slightly volatile
Long Term Debt To Capitalization0.260.170.317
Slightly volatile
Total Debt To Capitalization0.10.10591.4399
Slightly volatile
Quick Ratio9.014.67227.9202
Pretty Stable
Net Income Per E B T1.091.00.9735
Pretty Stable
Cash Ratio3.13.61943.6017
Pretty Stable
Days Of Sales Outstanding9.9610.481438.6209
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.171.01081.0598
Very volatile
Fixed Asset Turnover3.633.822418.0252
Slightly volatile
Debt Ratio0.07880.0830.7027
Slightly volatile
Price Sales Ratio3.153.310920.743
Very volatile
Asset Turnover0.210.40220.2035
Slightly volatile

Arcturus Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap433 M412.4 M226.2 M
Slightly volatile
Enterprise Value236 M224.7 M139 M
Slightly volatile

Arcturus Fundamental Market Drivers

Forward Price Earnings2.4777
Cash And Short Term Investments237 M

Arcturus Upcoming Events

26th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Arcturus Therapeutics Financial Statements

Arcturus Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Arcturus Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Arcturus Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Arcturus Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue21.9 M23.5 M
Total Revenue138.4 M145.3 M
Cost Of Revenue3.5 M3.4 M
Stock Based Compensation To Revenue 0.27  0.36 
Sales General And Administrative To Revenue 0.38  0.36 
Research And Ddevelopement To Revenue 1.41  2.44 
Revenue Per Share 5.13  2.75 
Ebit Per Revenue(0.69)(0.73)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Arcturus Stock Analysis

When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY